Share on :

Asset Summary

Daily Performance Report for BIIB ETF: Dec 26, 2024

Summary: The day started with BIIB ETF opening at $149.03 and closing at $148.36. The ETF showed weakness throughout the day, with the highest price observed at $149.03 and the lowest at $147.83. The underlying asset had a trading range of $1.20 Overall, it was a negative trading day for BIIB ETF, reflecting investor pessimism and market activity.

Change in Closing Price: There was a net decrease of $-0.67 or -0.45% in the closing price from the opening to the closing price over the day.

Volume Analysis: Trading volume for BIIB ETF was 20,062 units during Dec 26, 2024, indicating active market participation and investor interest.

Opening Price: The day started at $149.03.

Highest Price: The highest price observed during the day was $149.03.

Lowest Price: The lowest price observed during the day was $147.83.

Closing Price: The day ended at $148.36.

Asset Performance Metrics and Risk Characteristics:

Understanding asset performance is crucial for evaluating investment quality and making informed decisions. Metrics like trailing return and drawdown provide insights into how an asset has performed over time, its volatility, and the efficiency of its returns relative to risk. Performance indicators help assess the stability, risk, and reward of an investment, allowing investors and portfolio managers to make comparisons and strategize accordingly.

Asset Technical Analysis

Technical analysis involves evaluating an asset's price and volume data to forecast future movements and make informed trading decisions. By using various technical indicators and chart patterns, investors can gain insights into market trends, price momentum, and potential turning points. This section delves into essential technical metrics, including moving averages, pivot points, and other indicators that provide a snapshot of an asset's current technical stance. Analyzing these indicators helps investors identify entry and exit points, assess market sentiment, and refine their trading strategies. Explore the following technical analysis data to understand the asset's performance dynamics and make better-informed decisions.

Moving Averages

Moving Averages are commonly used to smooth out price data and identify trends over a specific period. Here’s a summary of the latest moving averages for various periods:

  • SMA (Simple Moving Average): Reflects the average price over a specific number of periods.
  • EMA (Exponential Moving Average): Gives more weight to recent prices, making it more responsive to new information.
  • WMA (Weighted Moving Average): Assigns a weight to each price, emphasizing more recent prices.
  • WEMA (Weighted Exponential Moving Average): Combines elements of both WMA and EMA for a more responsive moving average.

Reveal Your BIIB Trading Now

Unlock the full potential of BIIB with RankMyTrade Online’s cutting-edge automated trading system. Our platform provides precise price action analysis, advanced technical indicators, and powerful quantitative algorithms. Transform your trading strategy now and transform your trading experience today!

Explore Insights Now

Frequently Asked Questions

Biogen faces challenges such as competition from other pharmaceutical companies and regulatory hurdles in drug approval processes.

Yes, Biogen often collaborates with academic institutions and other companies for research and development purposes.

Biogen is committed to sustainability initiatives aimed at reducing its environmental impact and improving community health.

Biogen adheres to strict regulatory standards set by health authorities, conducting regular audits and reviews of its processes.

Biogen’s research contributes to advancements in treating complex neurological disorders, impacting patient care and treatment options.

Innovation is central to Biogen’s strategy, focusing on developing new therapies to address unmet medical needs in neurology.

Key products include Tecfidera, Avonex, and Spinraza, which are used for various neurological conditions.

Positive clinical trial results can lead to stock price increases and greater market confidence in Biogen’s products.

Recent developments include new clinical trial results and potential product launches; for the latest updates, check their press releases.

The outlook for Biogen’s stock can fluctuate based on market conditions, product performance, and overall economic factors.

Unleash Your BIIB Trading Now

Empower your trading with Rankmytrade. Our comprehensive platform delivers precise analysis and strategic insights for BIIB, designed to improve your trading outcomes. Boost your investment success with us and unlock new opportunities with our advanced system!

Disclaimers

The information displayed on this site is sourced from third-party providers and is believed to be reliable. RankMyTrade (RMT) has not independently verified this data and does not guarantee its accuracy. The information and calculations provided by RankMyTrade are for educational and informational purposes only and should not be construed as financial or investment advice.

With any investment, your capital is at risk. The value of your portfolio go down as well as up. Past performance is no guarantee of future results. By using this website, you accept our Terms of Service, Privacy Policy, and Payment Agreement.

Market data is provided in near real-time when available, but we do not guarantee its accuracy or timeliness.

Securities products are: Not FDIC insured · Not bank guaranteed · May lose value

Trademarks and logos are the property of their respective owners and do not represent endorsements of any kind. Unless otherwise noted, RankMyTrade and its affiliates are not partners, affiliates, or licensees of these companies.

Supported Assets & ETFs